Key Results fro PREFERMS: Real-World Patient Retention and Outcomes on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis

被引：0
|
作者：
Cree, Bruce [5 ]
Wynn, Daniel [1 ]
Cascione, Mark [4 ]
Meng, Xiangyi [2 ]
Schofield, Lesley [3 ]
Tenenbaum, Nadia [3 ]
机构：
[1] Consultants Neurol Ltd, Northbrook, IL USA
[2] Novartis, E Hanover, NJ USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Tampa Neurol Associates, Tampa, FL USA
[5] UCSF, Multiple Sclerosis Ctr, San Francisco, CA USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P3.115
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS
    Crayton, Heidi
    Steingo, Brian
    Huang, Deren
    Meng, Xiangyi
    Schofield, Lesley
    Johnson, Kristen
    Tenenbaum, Nadia
    [J]. NEUROLOGY, 2016, 86
  • [2] Post hoc results from PREFERMS: Volumetric MRI outcomes adjusted for exposure to fingolimod versus platform injectable disease-modifying therapies in early relapsing-remitting multiple sclerosis
    Arnold, Douglas L.
    Hunter, Samuel
    Cree, Bruce
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    [J]. NEUROLOGY, 2016, 87 (02) : E24 - E24
  • [3] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [4] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [5] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. NEUROLOGY, 2019, 92 (15)
  • [6] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 35 - 36
  • [7] Pregnancy and disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Oztekin, N. S.
    Oztekin, M. F.
    [J]. MULTIPLE SCLEROSIS, 2006, 12 : S95 - S96
  • [8] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    [J]. PLOS ONE, 2017, 12 (10):
  • [9] Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis
    Yano, Hajime
    Gonzalez, Cindy T.
    Healy, Brian C.
    Glanz, Bonnie I.
    Weiner, Howard L.
    Chitnis, Tanuja
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 47 - 47
  • [10] Injectable Disease-Modifying Therapy for Relapsing-Remitting Multiple Sclerosis: A Review of Adherence Data
    Caon, Christina
    Saunders, Carol
    Smrtka, Jennifer
    Baxter, Nancy
    Shoemaker, Jennifer
    [J]. JOURNAL OF NEUROSCIENCE NURSING, 2010, 42 (05) : S5 - S9
12345